Citicoline (CDP-choline) Explained Simply

1. What It Is About

Citicoline is also known as CDP-choline or cytidine diphosphate choline. The name describes its composition: cytidine, a phosphate group, and choline. Choline is a building block the body requires. In studies, citicoline is taken as a tablet; in acute medicine, it is also administered directly into the vein via infusion. Research on this substance spans several decades, with the earliest studies dating back to the late 1980s. Very different groups of people have been investigated: patients shortly after a stroke, following a head injury, with glaucoma, with Alzheimer’s dementia, older adults without dementia, as well as individuals with bipolar disorder and cocaine or methamphetamine dependence. Important to note: the studies measure very different outcomes. Some assess brain images or retinal and visual cortex measurements, while others evaluate test results, such as how well someone can remember words. These are not the same. A change in an image or measurement curve does not automatically mean a person feels better in everyday life.

2. What Studies Show

The clearest results are seen in people with memory and mood problems. In a study of 30 patients with Alzheimer’s dementia, citicoline or a placebo was administered for 12 weeks. Participants with a specific genetic trait (APOE-E4) showed a greater improvement in a memory test compared to the placebo group; the difference was more pronounced in mild dementia 10. In a second study involving 60 adults with depression and methamphetamine dependence over 12 weeks, mood scores improved more under citicoline than under placebo; participants also remained in the study longer and completed it more frequently 13. In 44 outpatients with a history of mania or hypomania and cocaine dependence, the citicoline group performed better in a word memory test after 12 weeks 11.

There are also findings related to the eye. In an open-label study, 50 patients with amblyopia (lazy eye) who were older than the age at which vision typically develops normally received citicoline for 15 days. In 46 of them, visual acuity improved, including in the healthy eye, and the effect persisted for at least four months 12. In children aged 4 to 13 with amblyopia who additionally received citicoline alongside eye patching, a better course was observed from the fifth month compared to patching alone 5. In glaucoma, eye drops containing citicoline were tested as an adjunct to pressure-lowering treatment: after three years, the course was slightly more favourable in the citicoline group, though the difference was not statistically significant 4.

A summary of several studies on stroke found that more treated patients were independent afterwards 3. However, in the largest single study with 899 patients, this advantage was not observed: the proportion of patients who showed significant improvement after 90 days was the same in both groups 6.

3. What Remains Unclear

Many of the large studies are only available as brief summaries that end before the results. In the ICTUS study with 2,298 stroke patients, the text provided lacks data on tolerability and outcomes 8. Similarly, the COBRIT study on head injuries with 1,213 patients ends its summary before presenting results 1. In another stroke study, the planned primary analysis could not be reliably conducted; later analyses showed no differences between groups 9. A review notes that two large clinical trials in stroke and head injury showed no benefit, while a possible effect was observed in slowly progressive conditions such as glaucoma; according to this review, the exact mechanism of action of citicoline is not sufficiently described 14.

4. What This Means in Practice

Citicoline has been studied for decades, and the evidence base is extensive. The clearest positive observations come from smaller studies on memory, mood, and the eye. The large studies on acute stroke, frequently cited, have so far shown no difference between citicoline and placebo. When reading reports, it is therefore important to first ask: Who was studied, what was measured, and how long after? An improved test score or altered measurement curve is not yet proof that someone functions better in daily life. What remains to be clarified: whether a subgroup of patients can be identified in whom treatment in the acute phase makes a difference, and whether the effect on the eye translates into a tangible benefit.

All details with study numbers and sources: Detailed page on citicoline (CDP-choline). For children: Citicoline (CDP-choline) for children.